Sarepta Therapeutics is a biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare, infectious, and other diseases.

 
 
 
 

Corporate Governance

Code of Business Conduct and Ethics

At Sarepta, we are committed to maintaining the highest standards of honest and ethical business conduct, including ensuring full, fair, accurate, timely and understandable disclosures in our public documents and reports, compliance with applicable laws, prompt internal reporting of violations of these standards and accountability for adherence to these standards. This Code reflects the business practices and principles of behavior that support this commitment.

Audit Committee Charter

The Audit Committee, consisting of three or more directors who are deemed independent in accordance with the listing standards of the Nasdaq Stock Market ("Nasdaq"), assist the Board of Directors in the exercise of its fiduciary responsibility of providing oversight of, among other things: (a) the integrity of the Company’s financial statements, financial reporting processes, and internal accounting and financial controls, (b) the Company’s compliance with legal and regulatory requirements, (c) the independent auditor’s qualifications and independence and (d) the performance of the Company’s independent auditor.

Compensation Committee Charter

The Compensation Committee, consisting of three or more directors who are deemed independent and meet any other eligibility requirements of NASDAQ, among other things, (a) discharges the responsibilities of the Board of Directors relating to compensation of the Company’s CEO and other executives as determined by the committee and (b) produces an annual report on executive compensation for inclusion in the Company’s annual proxy statement that complies with the rules and regulations of the Securities and Exchange Commission.

Nominating and Corporate Governance Committee Charter

The Nominating and Corporate Governance Committee, consisting of directors, all of whom are independent in accordance with the listing requirements of Nasdaq, is responsible for considering and making recommendations to the Board concerning the appropriate size, functions and corporate governance needs of the Board.

Corporate Governance: Committee Composition

Chairperson Chairperson Committee Member Member Financial Expert Financial Expert
 Audit CommitteeCompensation CommitteeNominating and Corporate Governance CommitteeResearch and Development Committee
Richard J. Barry 
Richard J. Barry

Richard J. Barry has served as a member of our Board since June 2015.  He also serves as chairman of our nominating and corporate governance committee and as a member and a financial expert of our audit committee. 

Richard J. Barry, a long time stockholder of the Company, has served as a director for Elcelyx Therapeutics, a pharmaceutical company, since February 2013 and is a Managing Member of GSM Fund, LLC, a fund established for the sole purpose of investing in Elcelyx.

Committee Member Committee Member Chairperson  
M. Kathleen Behrens, Ph.D. Financial Expert
M. Kathleen Behrens, Ph.D.

M. Kathleen Behrens, Ph.D., has served as a member of our Board since March 2009 and Chairwoman of the Board since April 2015. She also serves as chairwoman and as a financial expert of our audit committee and as a member of our nominating and corporate governance committee.

Dr. Behrens served as a member of the President's Council of Advisors on Science and Technology ("PCAST") from 2001 to early 2009 and as chairwoman of PCAST's Subcommittee on Personalized Medicine. She has se... 

Chairperson    Committee Member
Jean-Paul Kress, M.D. 
Jean-Paul Kress, M.D.
Committee Member Committee Member Committee Member  
Claude Nicaise, M.D. 
Claude Nicaise, M.D.

Claude Nicaise, M.D., has served as a member of our Board since June 2015.  He also serves as a member of our compensation committee and our research and development committee. 

Claude Nicaise, M.D., is the owner of Clinical Regulatory Services, a company providing advice on clinical and regulatory matters to biotechnology companies.

Prior to that, Dr. Nicaise was a Senior Vice President of Strategic Development and Global Regulatory Affairs at Alexion Pharmaceuti... 

  Chairperson   Committee Member
Hans Wigzell M.D., Ph.D. 
Hans Wigzell M.D., Ph.D.

Hans Wigzell, M.D., Ph.D., has served as a member of our Board since June 2010. He also serves as the chairman of our research and development committee and as a member of our nominating and corporate governance committee.

In the past five years, Dr. Wigzell has served as a director of Probi AB and currently serves as a director of RaySearch Laboratories AB, Swedish Orphan Biovitrum AB, and Valneva SE (a successor to Intercell AG). Since 2006, Dr. Wigzell has served as chairm... 

   Committee Member Chairperson